|Raven Biotechnologies, 7/2008|
|Series C, 5/2006 |
Caisse de Depot et Placement du Quebec
Biogen Idec New Ventures
Texas Pacific Group
Red Abbey Venture Partners
|Private Equity, 1/2011 ||$12M|
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.
The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company’s Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.
The company was founded in 2000 and is headquartered in Rockville, Maryland.